https://scholars.lib.ntu.edu.tw/handle/123456789/495013
標題: | Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis | 作者: | CHIA-LIN HSU JEN-HAU CHEN KUAN-YU CHEN JIN-YUAN SHIH CHIH-HSIN YANG CHONG-JEN YU PAN-CHYR YANG |
公開日期: | 2015 | 出版社: | Elsevier Ltd | 卷: | 6 | 期: | 1 | 起(迄)頁: | 38-45 | 來源出版物: | Journal of Geriatric Oncology | 摘要: | Objectives: Data on the treatment modalities and prognostic factors for elderly patients with advanced non-small cell lung cancer (NSCLC) remain limited. This study investigates the impact of age and comorbidities on treatment modalities and patient prognosis. Materials and Methods: From January 2004 to December 2008, patients aged ?. 70. years old and diagnosed with stage IIIB or IV NSCLC were included retrospectively. Their clinical characteristics were reviewed and analyzed. Comorbidity status was evaluated using Charlson comorbidity index (CCI) and simplified comorbidity score (SCS). Results: A total of 576 patients were included in this analysis. Four hundred and nineteen patients (72.7%) received systemic therapy, including 182 (31.6%) patients who received chemotherapy, and 237 (41.1%) patients who received epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as initial treatment. Patients aged ?. 80 were less likely to receive chemotherapy as initial treatment than those aged 70-79 (12.3% vs. 40.9%, p<. 0.001). There was no significant difference in proportion of chemotherapy between patients with high and low comorbidity score. Receipt of systemic therapy, male gender, PS. ?. 2, and histologic type were associated with a poorer prognosis. In the multivariate analysis, which included the comorbidity items of SCS, cigarette smoking (HR: 1.73, 95% CI: 1.36-2.21), age ?. 80 (HR: 1.30, 95% CI: 1.01-1.67), and PS ?. 2 (HR: 3.07, 95% CI: 2.37-3.98) were associated with a shorter survival period. Conclusion: Age may limit chemotherapy use for elderly patients with NSCLC. Cigarette smoking is an important independent prognostic factor for this particular population. ? 2014 Elsevier Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920872437&doi=10.1016%2fj.jgo.2014.09.178&partnerID=40&md5=cecaecab0b1e4fbefeb22ea3c03c617f https://scholars.lib.ntu.edu.tw/handle/123456789/495013 |
ISSN: | 1879-4068 | DOI: | 10.1016/j.jgo.2014.09.178 | SDG/關鍵字: | afatinib; carboplatin; cisplatin; docetaxel; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; fluorouracil; gefitinib; gemcitabine; navelbine; paclitaxel; platinum complex; epidermal growth factor receptor; protein kinase inhibitor; adenocarcinoma; advanced cancer; age; aged; alcoholism; Article; cancer combination chemotherapy; cancer incidence; cancer prognosis; cancer staging; cancer survival; cardiovascular disease; central nervous system disease; Charlson Comorbidity Index; chronic obstructive lung disease; comorbidity; controlled study; cytology; diabetes mellitus; EGFR gene; female; gene mutation; health status; histopathology; human; human tissue; hypertension; kidney failure; major clinical study; male; malignant neoplastic disease; monotherapy; multivariate analysis; non small cell lung cancer; overall survival; respiratory tract disease; sex difference; simplified comorbidity score; single drug dose; smoking; social support; squamous cell carcinoma; survival time; undifferentiated carcinoma; univariate analysis; very elderly; age; antagonists and inhibitors; Carcinoma, Non-Small-Cell Lung; comorbidity; Lung Neoplasms; prognosis; retrospective study; risk factor; Taiwan; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Female; Humans; Lung Neoplasms; Male; Prognosis; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor; Retrospective Studies; Risk Factors; Smoking; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。